Antiphospholipid antibodies: What’s new in 2022? (notice n° 136079)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02183cam a2200193 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250112021452.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Melicine, Sophie |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Antiphospholipid antibodies: What’s new in 2022? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2022.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 76 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Antiphospholipid syndrome (APS) is a clinical-biological entity defined by the combination of thrombotic events and/or obstetric complications and the presence of persistent antiphospholipid antibodies (APLAs) detected by coagulation tests (lupus anticoagulant, LAC) and/or immunological assays (anticardiolipin and anti-glycoprotein-beta-I antibodies). The increased use of direct oral anticoagulants (DOACs) for the treatment of venous thromboembolism (VTE) poses a challenge for hematology laboratories when it comes to diagnosing APS. DOACs interfere with LAC screening and confirmation tests, resulting in a risk of false positive results. To avoid these interferences, several solutions are suggested. Some of them rely on the use of DOAC-reversal systems (activated charcoal tablet, filter system); others on the use of reagents insensitive to DOAC presence in the sample. Detection of anti-phosphatidylserine/prothrombin antibodies may be helpful because they are strongly associated with the presence of LAC and are increasingly recognized as a useful tool in the diagnosis and prognosis of APS. Finally, positivity of LA in the context of a viral infection is frequent and not specific to APS. During the Covid-19 pandemic, many patients developed arterial and/or venous thromboembolism that could suggest testing for APLAs. The link between LAC and a risk of VTE or in-hospital mortality in hospitalized Covid-19 patients was not demonstrated. Moreover, APLAs do not persist after Covid-19. Currently, testing for APLAs in Covid-19 patients is not recommended. |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gendron, Nicolas |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Darnige, Luc |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mauge, Laetitia |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Annales de Biologie Clinique | 80 | 4 | 2022-07-01 | p. 333-343 | 0003-3898 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/journal-annales-de-biologie-clinique-2022-4-page-333?lang=en">https://shs.cairn.info/journal-annales-de-biologie-clinique-2022-4-page-333?lang=en</a> |
Pas d'exemplaire disponible.
Réseaux sociaux